Alpine Immune Sciences (ALPN) Given a $13.00 Price Target by Oppenheimer Analysts

Oppenheimer set a $13.00 price objective on Alpine Immune Sciences (NASDAQ:ALPN) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock.

ALPN has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a hold rating to a sell rating in a research report on Wednesday, November 14th. ValuEngine raised shares of Alpine Immune Sciences from a sell rating to a hold rating in a research report on Tuesday, October 23rd. Piper Jaffray Companies started coverage on shares of Alpine Immune Sciences in a research report on Thursday, September 27th. They issued an overweight rating and a $12.00 price objective for the company. Finally, Raymond James started coverage on shares of Alpine Immune Sciences in a research report on Monday, August 13th. They issued a buy rating and a $13.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $12.67.

Alpine Immune Sciences stock opened at $4.80 on Monday. The firm has a market capitalization of $66.46 million, a P/E ratio of -4.00 and a beta of 0.96. Alpine Immune Sciences has a 1-year low of $4.51 and a 1-year high of $11.75. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.31). Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 43.25%. On average, research analysts anticipate that Alpine Immune Sciences will post -2.62 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after acquiring an additional 11,200 shares during the period. DRW Securities LLC boosted its holdings in shares of Alpine Immune Sciences by 138.7% during the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after buying an additional 14,143 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after buying an additional 21,124 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after buying an additional 18,052 shares during the period. 54.74% of the stock is owned by institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Article: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply